SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marianne Schmid, Jesse D. Sammon, Gally Reznor, Victor Kapoor, Jacqueline M. Speed, Firas A. Abdollah, Akshay Sood, Felix K.-H. Chun, Adam S. Kibel, Mani Menon, Margit Fisch, Maxine Sun, Quoc-Dien Trinh, Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events, BJU International, 2016, 117, 2
  2. 2
    Y. Yamaguchi, Y. Hayashi, Y. Ishizuya, K. Takeda, Y. Nakai, Y. Arai, M. Nakayama, K.-i. Kakimoto, K. Nishimura, A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score, Japanese Journal of Clinical Oncology, 2015, 45, 2, 197

    CrossRef

  3. 3
    Paul L. Nguyen, Shabbir M.H. Alibhai, Shehzad Basaria, Anthony V. D’Amico, Philip W. Kantoff, Nancy L. Keating, David F. Penson, Derek J. Rosario, Bertrand Tombal, Matthew R. Smith, Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them, European Urology, 2015, 67, 5, 825

    CrossRef

  4. 4
    J. Sáenz Medina, J. Carballido Rodríguez, Aspectos fisiopatológicos implicados en la patología urologica asociada al síndrome metabólico. Revisión bibliográfica, Actas Urológicas Españolas, 2015,

    CrossRef

  5. You have free access to this content5
    Prue Cormie, Daniel A. Galvão, Nigel Spry, David Joseph, Raphael Chee, Dennis R. Taaffe, Suzanne K. Chambers, Robert U. Newton, Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial, BJU International, 2015, 115, 2
  6. 6
    Jeffrey Shevach, Emily Jane Gallagher, Teena Kochukoshy, Victoria Gresia, Manpreet Brar, Matthew D. Galsky, William K. Oh, Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer, Frontiers in Oncology, 2015, 5,

    CrossRef

  7. 7
    Brian Winters, Stephen Plymate, Steven B. Zeliadt, Sarah Holt, Xiaotun Zhang, Elaine Hu, Daniel W. Lin, Colm Morrissey, Bryan Wooldridge, John L. Gore, Michael P. Porter, Jonathan L. Wright, Metformin effects on biochemical recurrence and metabolic signaling in the prostate, The Prostate, 2015, 75, 15
  8. 8
    Bradley A. Wall, Daniel A. Galvão, Naeem Fatehee, Dennis R. Taaffe, Nigel Spry, David Joseph, Robert U. Newton, Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation, Advances in Urology, 2015, 2015, 1

    CrossRef

  9. 9
    Pilar Ma Samper Ots, Julia Luisa Muñoz García, Yesika Ríos Kavadoy, Ma Luz Couselo Paniagua, Elena Villafranca Iturre, Milagrosa Rodríguez Liñán, Ana María Pérez Casas, Rodrigo Muelas Soria, Blanca Ludeña Martínez, José López Torrecilla, Manuel Casaña Giner, Almudena Zapatero Laborda, Ma Magdalena Márquez García-Salazar, SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study, Reports of Practical Oncology & Radiotherapy, 2015, 20, 5, 370

    CrossRef

  10. 10
    Joshua R. Gonzalez, Irwin Goldstein, Testosterone replacement and cardiovascular disease risk, Cardiovascular Endocrinology, 2015, 4, 3, 100

    CrossRef

  11. 11
    Juan Morote, Antonio Gómez-Caamaño, José L. Alvarez-Ossorio, Daniel Pesqueira, Angel Tabernero, Francisco Gómez Veiga, José A. Lorente, Mariano Porras, Juan J. Lobato, María J. Ribal, Jacques Planas, The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy, The Journal of Urology, 2015, 193, 6, 1963

    CrossRef

  12. 12
    Guadalupe Navarro, Camille Allard, Weiwei Xu, Franck Mauvais-Jarvis, The role of androgens in metabolism, obesity, and diabetes in males and females, Obesity, 2015, 23, 4
  13. 13
    Abdulmaged M. Traish, Adverse health effects of testosterone deficiency (TD) in men, Steroids, 2014, 88, 106

    CrossRef

  14. 14
    C. A. Allan, V. R. Collins, M. Frydenberg, R. I. McLachlan, K. L. Matthiesson, Androgen deprivation therapy complications, Endocrine Related Cancer, 2014, 21, 4, T119

    CrossRef

  15. 15
    I.-C. Yu, H.-Y. Lin, J. D. Sparks, S. Yeh, C. Chang, Androgen Receptor Roles in Insulin Resistance and Obesity in Males: The Linkage of Androgen-Deprivation Therapy to Metabolic Syndrome, Diabetes, 2014, 63, 10, 3180

    CrossRef

  16. 16
    Joanne M. Harrington, Dawn C. Schwenke, Dana R. Epstein, Donald E. Bailey, Androgen-Deprivation Therapy and Metabolic Syndrome in Men With Prostate Cancer, Oncology Nursing Forum, 2014, 41, 1, 21

    CrossRef

  17. 17
    Christina G. Jespersen, Mette Nørgaard, Michael Borre, Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study, European Urology, 2014, 65, 4, 704

    CrossRef

  18. 18
    P. Y. Takahashi, P. Y. Liu, J. D. Veldhuis, Distinct roles of age and abdominal visceral fat in reducing androgen receptor-dependent negative feedback on LH secretion in healthy men, Andrology, 2014, 2, 4
  19. You have free access to this content19
    David Chang, David J Joseph, Martin A Ebert, Daniel A Galvão, Dennis R Taaffe, James W Denham, Robert U Newton, Nigel A Spry, Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer, Journal of Medical Imaging and Radiation Oncology, 2014, 58, 2
  20. 20
    Denise Soltow Hershey, Ashley Leak Bryant, Jill Olausson, Ellen D. Davis, Veronica J. Brady, Marilyn Hammer, Hyperglycemic-Inducing Neoadjuvant Agents Used in Treatment of Solid Tumors: A Review of the Literature, Oncology Nursing Forum, 2014, 41, 6, E343

    CrossRef

  21. 21
    BRADLEY A. WALL, DANIEL A. GALVÃO, NAEEM FATEHEE, DENNIS R. TAAFFE, NIGEL SPRY, DAVID JOSEPH, ROBERT U. NEWTON, Maximal Exercise Testing of Men with Prostate Cancer Being Treated with Androgen Deprivation Therapy, Medicine & Science in Sports & Exercise, 2014, 46, 12, 2210

    CrossRef

  22. 22
    J. Morote, J. Ropero, J. Planas, A. Celma, J. Placer, R. Ferrer, I. de Torres, Metabolic syndrome in patients with prostate cancer undergoing androgen suppression, Actas Urológicas Españolas (English Edition), 2014, 38, 5, 285

    CrossRef

  23. 23
    Christian Rothermundt, Stefanie Hayoz, Arnoud J. Templeton, Ralph Winterhalder, Räto T. Strebel, Daniela Bärtschi, Michael Pollak, Lillianne Lui, Kathrin Endt, Ralph Schiess, Jan H. Rüschoff, Richard Cathomas, Silke Gillessen, Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09), European Urology, 2014, 66, 3, 468

    CrossRef

  24. 24
    C Albany, N M Hahn, Novel bone-targeting agents in prostate cancer, Prostate Cancer and Prostatic Disease, 2014, 17, 2, 112

    CrossRef

  25. 25
    Berardino De Bari, Filippo Alongi, Michela Buglione, Franco Campostrini, Alberto Briganti, Genoveffa Berardi, Giuseppe Petralia, Massimo Bellomi, Arturo Chiti, Andrei Fodor, Nazareno Suardi, Cesare Cozzarini, Di Muzio Nadia, Marta Scorsetti, Roberto Orecchia, Francesco Montorsi, Filippo Bertoni, Stefano Maria Magrini, Barbara Alicja Jereczek-Fossa, Salvage therapy of small volume prostate cancer nodal failures: A review of the literature, Critical Reviews in Oncology/Hematology, 2014, 90, 1, 24

    CrossRef

  26. 26
    J. Morote, J. Ropero, J. Planas, A. Celma, J. Placer, R. Ferrer, I. de Torres, Síndrome metabólico en pacientes con cáncer de próstata sometidos a supresión androgénica, Actas Urológicas Españolas, 2014, 38, 5, 285

    CrossRef

  27. 27
    Gaëtan Prévost, Florence Eas, Jean-Marc Kuhn, Testostérone plasmatique, obésité, syndrome métabolique et diabète, La Presse Médicale, 2014, 43, 2, 186

    CrossRef

  28. 28
    Andrea M. Isidori, Giovanni Corona, Antonio Aversa, Daniele Gianfrilli, Emmanuele A. Jannini, Carlo Foresta, Mario Maggi, Andrea Lenzi, SIAMS-ED Study Group, The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil, International Journal of Endocrinology, 2014, 2014, 1

    CrossRef

  29. 29
    Jean-Marc Kuhn, Gaëtan Prévost, Traitement androgénique des hypoandrismes masculins, La Presse Médicale, 2014, 43, 2, 196

    CrossRef

  30. 30
    Landon W. Trost, Ege Serefoglu, Ahmet Gokce, Brian J. Linder, Alton O. Sartor, Wayne J.G. Hellstrom, Androgen Deprivation Therapy Impact on Quality of Life and Cardiovascular Health, Monitoring Therapeutic Replacement, The Journal of Sexual Medicine, 2013, 10,
  31. 31
    Stephen E. Gilbert, Garry A. Tew, Liam Bourke, Edward M. Winter, Derek J. Rosario, Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer, Experimental Physiology, 2013, 98, 9
  32. 32
    Anya Burton, Richard M. Martin, Jeff Holly, J. Athene Lane, Jenny L. Donovan, Freddie C. Hamdy, David E. Neal, Kate Tilling, Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study, Cancer Causes & Control, 2013, 24, 2, 323

    CrossRef

  33. 33
    Shehzad Basaria, Editorial Comment, The Journal of Urology, 2013, 189, 1, S43

    CrossRef

  34. 34
    G. Huang, S. Bhasin, E. R. Tang, A. Aakil, S. W. Anderson, H. Jara, M. Davda, T. G. Travison, S. Basaria, Effect of Testosterone Administration on Liver Fat in Older Men With Mobility Limitation: Results From a Randomized Controlled Trial, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2013, 68, 8, 954

    CrossRef

  35. 35
    T. Hvid, K. Winding, A. Rinnov, T. Dejgaard, C. Thomsen, P. Iversen, K. Brasso, K. J. Mikines, G. van Hall, B. Lindegaard, T. P. J. Solomon, B. K. Pedersen, Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy, Endocrine Related Cancer, 2013, 20, 5, 621

    CrossRef

  36. 36
    B. Carlos García, Enfermedades endocrinas en el adulto mayor, Revista Médica Clínica Las Condes, 2013, 24, 5, 866

    CrossRef

  37. 37
    Joanne M. Harrington, Dawn C. Schwenke, Dana R. Epstein, Exercise Preferences Among Men With Prostate Cancer Receiving Androgen-Deprivation Therapy, Oncology Nursing Forum, 2013, 40, 5, E358

    CrossRef

  38. 38
    Jennifer C. Regan, Linda Partridge, Gender and longevity: Why do men die earlier than women? Comparative and experimental evidence, Best Practice & Research Clinical Endocrinology & Metabolism, 2013, 27, 4, 467

    CrossRef

  39. 39
    J L Wright, S R Plymate, M P Porter, J L Gore, D W Lin, E Hu, S B Zeliadt, Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer, Prostate Cancer and Prostatic Diseases, 2013,

    CrossRef

  40. 40
    Rahul R. Aggarwal, Charles J. Ryan, June M. Chan, Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?, Urologic Oncology: Seminars and Original Investigations, 2013, 31, 5, 522

    CrossRef

  41. 41
    Michele Lodde, Louis Lacombe, Angelo Naselli, Paolo Puppo, Michael Mian, Yves Fradet, Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy, World Journal of Urology, 2013, 31, 2, 293

    CrossRef

  42. 42
    B.J. Schmitz-Dräger, G. Lümmen, E. Bismarck, C. Fischer, Metabolisches Syndrom und Prostatakarzinom, Der Urologe, 2013, 52, 6, 842

    CrossRef

  43. 43
    I.-C. Yu, H.-Y. Lin, N.-C. Liu, J. D. Sparks, S. Yeh, L.-Y. Fang, L. Chen, C. Chang, Neuronal Androgen Receptor Regulates Insulin Sensitivity via Suppression of Hypothalamic NF- B-Mediated PTP1B Expression, Diabetes, 2013, 62, 2, 411

    CrossRef

  44. 44
    Jennifer H. Gunter, Phoebe L. Sarkar, Amy A. Lubik, Colleen C. Nelson, New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication, International Journal of Cell Biology, 2013, 2013, 1

    CrossRef

  45. 45
    Stanislav Ziaran, Frederico Manuel Goncalves, Jan Breza, Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control, World Journal of Urology, 2013, 31, 2, 289

    CrossRef

  46. 46
    Michael H. Antoni, Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer, Brain, Behavior, and Immunity, 2013, 30, S88

    CrossRef

  47. 47
    Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison, Shalender Bhasin, Risks and benefits of testosterone therapy in older men, Nature Reviews Endocrinology, 2013, 9, 7, 414

    CrossRef

  48. 48
    J.-E. Terrier, N. Mottet, Syndrome métabolique et insulinorésistance chez les patients atteints de cancer de la prostate traités par suppression androgénique hormonale, Progrès en Urologie, 2013, 23, 2, 88

    CrossRef

  49. 49
    Daniel J. Moskovic, Andre B. Araujo, Larry I. Lipshultz, Mohit Khera, The 20-Year Public Health Impact and Direct Cost of Testosterone Deficiency in U.S. Men, The Journal of Sexual Medicine, 2013, 10, 2
  50. You have free access to this content50
    Jenny P. Nobes, Stephen E.M. Langley, Tanya Klopper, David Russell-Jones, Robert W. Laing, A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy, BJU International, 2012, 109, 10
  51. 51
    Lauren Collins, Shehzad Basaria, Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications, Asian Journal of Andrology, 2012, 14, 2, 222

    CrossRef

  52. 52
    Jeremy B. Shelton, Jacob Rajfer, Androgen Deficiency in Aging and Metabolically Challenged Men, Urologic Clinics of North America, 2012, 39, 1, 63

    CrossRef

  53. 53
    Giovanni Corona, Mauro Gacci, Elisabetta Baldi, Rosa Mancina, Gianni Forti, Mario Maggi, Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects, The Journal of Sexual Medicine, 2012, 9, 3
  54. 54
    Kerry J. McInnes, Lee B. Smith, Nicole I. Hunger, Philippa T.K. Saunders, Ruth Andrew, Brian R. Walker, Deletion of the Androgen Receptor in Adipose Tissue in Male Mice Elevates Retinol Binding Protein 4 and Reveals Independent Effects on Visceral Fat Mass and on Glucose Homeostasis, Diabetes, 2012, 61, 5, 1072

    CrossRef

  55. 55
    Mikio Namiki, Satoru Ueno, Yasuhide Kitagawa, Takashi Fukagai, Hideyuki Akaza, Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective, Asian Journal of Andrology, 2012, 14, 3, 451

    CrossRef

  56. 56
    Hasan S. Sağlam, Osman Köse, Şükrü Kumsar, Salih Budak, Öztuğ Adsan, Fasting Blood Glucose and Lipid Profile Alterations following Twelve-Month Androgen Deprivation Therapy in Men with Prostate Cancer, The Scientific World Journal, 2012, 2012, 1

    CrossRef

  57. 57
    C. Hennequin, P. Mongiat-Artus, L. Quero, D. Pouessel, S. Culine, Les effets secondaires de l’hormonothérapie et leur gestion, Oncologie, 2012, 14, 2, 96

    CrossRef

  58. 58
    Martin M. Miner, Men’s Health in Primary Care: An Emerging Paradigm of Sexual Function and Cardiometabolic Risk, Urologic Clinics of North America, 2012, 39, 1, 1

    CrossRef

  59. 59
    Carolyn A Allan, Veronica R Collins, Mark Frydenberg, Robert I McLachlan, Kati L Matthiesson, Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy, International Journal of Urological Nursing, 2012, 6, 1
  60. 60
    M. Arafa, W. Zohdy, S. Aboulsoud, R. Shamloul, Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus, Andrologia, 2012, 44,
  61. 61
    Donovan A. McGrowder, Lennox Anderson Jackson, Tazhmoye V. Crawford, Prostate Cancer and Metabolic Syndrome: Is there a link?, Asian Pacific Journal of Cancer Prevention, 2012, 13, 1, 1

    CrossRef

  62. 62
    Satyajit Kosuri, Naveed H. Akhtar, Michael Smith, Joseph R. Osborne, Scott T. Tagawa, Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy, Advances in Urology, 2012, 2012, 1

    CrossRef

  63. 63
    Shehzad Basaria, Shalender Bhasin, Targeting the Skeletal Muscle–Metabolism Axis in Prostate-Cancer Therapy, New England Journal of Medicine, 2012, 367, 10, 965

    CrossRef

  64. 64
    Jennifer H. Gunter, Amy A. Lubik, Ian McKenzie, Michael Pollak, Colleen C. Nelson, The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer, Advances in Urology, 2012, 2012, 1

    CrossRef

  65. You have free access to this content65
    Howard S. Kim, Daniel M. Moreira, Matthew R. Smith, Joseph C. Presti, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Stephen J. Freedland, A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, BJU International, 2011, 107, 6
  66. 66
    Farid Saad, Ahmad Haider, Erik J. Giltay, Louis J.G. Gooren, Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome, Hormone Molecular Biology and Clinical Investigation, 2011, 6, 1

    CrossRef

  67. 67
    Abdulmaged M. Traish, Bassima Abdallah, George Yu, Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease, Hormone Molecular Biology and Clinical Investigation, 2011, 8, 1

    CrossRef

  68. 68
    S. Cleffi, A.S. Neto, L.O. Reis, Priscila Maia, F. Fonseca, M.L. Wroclawski, M. Neves, A.C.L. Pompeo, A. Del Giglio, E.F. Faria, M. Tobias-Machado, Androgen deprivation therapy and morbid obesity: Do they share cardiovascular risk through metabolic syndrome?, Actas Urológicas Españolas (English Edition), 2011, 35, 5, 259

    CrossRef

  69. 69
    Elisa Martín-Merino, Saga Johansson, Thomas Morris, Luis A. García Rodríguez, Androgen Deprivation Therapy and the Risk of Coronary Heart Disease and Heart Failure in Patients with Prostate Cancer, Drug Safety, 2011, 34, 11, 1061

    CrossRef

  70. 70
    Juan-Jie Bo, Chao Zhang, Lian-Hua Zhang, Ping Liu, Jian-Jun Sha, Jian-Wei Lv, Dong-Ming Liu, Yi-Ran Huang, Zheng Li, Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks, Asian Journal of Andrology, 2011, 13, 6, 833

    CrossRef

  71. 71
    G. Corona, E. Baldi, M. Maggi, Androgen regulation of prostate cancer: Where are we now?, Journal of Endocrinological Investigation, 2011, 34, 3, 232

    CrossRef

  72. 72
    A. A. Yassin, F. Akhras, A. I. El-Sakka, F. Saad, Cardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency, Andrologia, 2011, 43, 1
  73. 73
    Hassanabbas Z Mohamedali, Shabbir MH Alibhai, Does androgen deprivation therapy increase diabetes risk?, Diabetes Management, 2011, 1, 6, 551

    CrossRef

  74. 74
    Jin Wook Kim, Je Jong Kim, Du Geon Moon, Effects of Androgen on the Cardiovascular System in the Aging Male, Korean Journal of Andrology, 2011, 29, 1, 10

    CrossRef

  75. 75
    Franck Mauvais-Jarvis, Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity, Trends in Endocrinology & Metabolism, 2011, 22, 1, 24

    CrossRef

  76. 76
    Erik D. Hanson, Ben F. Hurley, Intervening on the Side Effects of Hormone-Dependent Cancer Treatment: The Role of Strength Training, Journal of Aging Research, 2011, 2011, 1

    CrossRef

  77. 77
    Bhavin R. Shastri, Subhashini Yaturu, Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer, Prostate Cancer, 2011, 2011, 1

    CrossRef

  78. 78
    S. Cleffi, A.S. Neto, L.O. Reis, Priscila Maia, F. Fonseca, M.L. Wroclawski, M. Neves, A.C.L. Pompeo, A. Del Giglio, E.F. Faria, M. Tobias-Machado, Terapia de privación de andrógenos y obesidad mórbida: ¿tienen en común el riesgo cardiovascular por síndrome metabólico?, Actas Urológicas Españolas, 2011, 35, 5, 259

    CrossRef

  79. 79
    Abdulmaged M. Traish, Martin M. Miner, Abraham Morgentaler, Michael Zitzmann, Testosterone Deficiency, The American Journal of Medicine, 2011, 124, 7, 578

    CrossRef

  80. 80
    Andre T. Guay, Abdulmaged Traish, Testosterone Deficiency and Risk Factors in the Metabolic Syndrome: Implications for Erectile Dysfunction, Urologic Clinics of North America, 2011, 38, 2, 175

    CrossRef

  81. 81
    Farid Saad, Louis J. Gooren, The Role of Testosterone in the Etiology and Treatment of Obesity, the Metabolic Syndrome, and Diabetes Mellitus Type 2, Journal of Obesity, 2011, 2011, 1

    CrossRef

  82. 82
    X.- X. He, S. M. Tu, M.- H. Lee, S.- C. J. Yeung, Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients, Annals of Oncology, 2011, 22, 12, 2640

    CrossRef

  83. 83
    Shi-Jin Zhang, Marie Sandström, Maria Ahlsén, Niklas Ivarsson, Hua Zhu, Jianjie Ma, Jian-Ming Ren, Håkan Westerblad, Abram Katz, 2-Methoxyoestradiol inhibits glucose transport in rodent skeletal muscle, Experimental Physiology, 2010, 95, 8
  84. 84
    Howard S Kim, Stephen J Freedland, Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management, Current Opinion in Supportive and Palliative Care, 2010, 4, 3, 147

    CrossRef

  85. 85
    Claude C. Schulman, Jacques Irani, Juan Morote, Jack A. Schalken, Francesco Montorsi, Piotr L. Chlosta, Axel Heidenreich, Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review, European Urology Supplements, 2010, 9, 7, 675

    CrossRef

  86. 86
    Ahmad Haider, Louis J.G. Gooren, Pawin Padungtod, Farid Saad, Beneficial effects of 2 years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and C-reactive protein, Hormone Molecular Biology and Clinical Investigation, 2010, 1, 1

    CrossRef

  87. 87
    Amanda J. Redig, Hidayatullah G. Munshi, Care of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying Therapy, The American Journal of Medicine, 2010, 123, 1, 87.e1

    CrossRef

  88. 88
    Takamitsu Inoue, Mahvash Zakikhani, Stéphanie David, Carolyn Algire, Marie-José Blouin, Michael Pollak, Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man, The Prostate, 2010, 70, 15
  89. You have free access to this content89
    Svetlana Y. Kalinchenko, Yuliya A. Tishova, George J. Mskhalaya, Louis J. G. Gooren, Erik J. Giltay, Farid Saad, Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study, Clinical Endocrinology, 2010, 73, 5
  90. 90
    Antonio Aversa, R. Bruzziches, D. Francomano, G. Spera, A. Lenzi, Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome, Journal of Endocrinological Investigation, 2010, 33, 11, 776

    CrossRef

  91. 91
    Karen Choong, Shehzad Basaria, Emerging cardiometabolic complications of androgen deprivation therapy, The Aging Male, 2010, 13, 1, 1

    CrossRef

  92. You have free access to this content92
    Jacques Buvat, Mario Maggi, Louis Gooren, Andre T. Guay, Joel Kaufman, Abraham Morgentaler, Claude Schulman, Hui Meng Tan, Luiz Otavio Torres, Aksam Yassin, Michael Zitzmann, Endocrine Aspects of Male Sexual Dysfunctions, The Journal of Sexual Medicine, 2010, 7, 4pt2
  93. 93
    Francesc Casas, Josep María Borràs, Ferran Ferrer, Núria Guanyabens, Rafael Gutiérrez del Pozo, Concha León, José López Torrecilla, Begoña Mellado, Joan Morote, Manel Puig, María José Ribal, Carme Ruscalleda, Agustí Serra, Valentí Valls, Almudena Zapatero, Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment, Clinical and Translational Oncology, 2010, 12, 5, 346

    CrossRef

  94. 94
    Dale R. Shepard, Derek Raghavan, Innovations in the systemic therapy of prostate cancer, Nature Reviews Clinical Oncology, 2010, 7, 1, 13

    CrossRef

  95. 95
    Henry Botto, Yann Neuzillet, Thierry Lebret, Philippe Camparo, Vincent Molinie, Jean-Pierre Raynaud, Preoperative low serum testosterone levels are associated with tumor aggressiveness in radical prostatectomy treated cancer patients, Hormone Molecular Biology and Clinical Investigation, 2010, 2, 1

    CrossRef

  96. 96
    M. Schubert, F. Jockenhövel, Testosteron und das metabolische Syndrom, Der Urologe, 2010, 49, 1, 47

    CrossRef

  97. 97
    T.H. Jones, Testosterone deficiency: a risk factor for cardiovascular disease?, Trends in Endocrinology & Metabolism, 2010, 21, 8, 496

    CrossRef

  98. 98
    Diala El-Maouche, Adrian Dobs, Principles of Gender-Specific Medicine, 2010,

    CrossRef

  99. 99
    Sherita Hill Golden, Principles of Gender-Specific Medicine, 2010,

    CrossRef

  100. 100
    Hendrik Isbarn, Laurent Boccon-Gibod, Peter R. Carroll, Francesco Montorsi, Claude Schulman, Matthew R. Smith, Cora N. Sternberg, Urs E. Studer, Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks, European Urology, 2009, 55, 1, 62

    CrossRef

  101. 101
    D A Galvão, D R Taaffe, N Spry, D Joseph, R U Newton, Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure, Prostate Cancer and Prostatic Diseases, 2009, 12, 3, 233

    CrossRef

  102. 102
    Ronald Tamler, Diabetes, obesity, and erectile dysfunction, Gender Medicine, 2009, 6, 4

    CrossRef

  103. 103
    Valéria Helena Alves Cagnon Quitete, Wagner José Fávaro, Dystroglycan patterns on the prostate of non-obese diabetic mice submitted to glycaemic control, International Journal of Experimental Pathology, 2009, 90, 2
  104. 104
    Shehzad Basaria, Editorial Comment, The Journal of Urology, 2009, 181, 5, 2007

    CrossRef

  105. 105
    Preetika Sharma, Amy Wisniewski, Milena Braga-Basaria, Xiaoqiang Xu, Mary Yep, Samuel Denmeade, Adrian S. Dobs, Theodore DeWeese, Michael Carducci, Shehzad Basaria, Lack of an Effect of High Dose Isoflavones in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy, The Journal of Urology, 2009, 182, 5, 2265

    CrossRef

  106. 106
    P. Mongiat-Artus, M. Peyromaure, P. Richaud, P. Beuzeboc, C. Bastide, F. Cornud, N. Gaschignard, V. Molinié, F. Rozet, F. Staerman, M. Soulié, L. Salomon, Le traitement hormonal du cancer de la prostate chez le patient âgé, Progrès en Urologie, 2009, 19, S151

    CrossRef

  107. 107
    J.P. Nobes, S.E.M. Langley, R.W. Laing, Metabolic Syndrome and Prostate Cancer: A Review, Clinical Oncology, 2009, 21, 3, 183

    CrossRef

  108. 108
    Marina Mourtzakis, Megan Bedbrook, Muscle atrophy in cancer: a role for nutrition and exercise, Applied Physiology, Nutrition, and Metabolism, 2009, 34, 5, 950

    CrossRef

  109. 109
    Shehzad Basaria, Prostate cancer: Cardiovascular mortality and androgen deprivation, Nature Reviews Urology, 2009, 6, 5, 252

    CrossRef

  110. 110
    Lockwood G. Taylor, Steven E. Canfield, Xianglin L. Du, Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer, Cancer, 2009, 115, 11
  111. 111
    Noel N. Kim, Sex Steroid Hormones in Diabetes-Induced Sexual Dysfunction: Focus on the Female Gender, The Journal of Sexual Medicine, 2009, 6, S3
  112. 112
    Michael Zitzmann, Testosterone deficiency, insulin resistance and the metabolic syndrome, Nature Reviews Endocrinology, 2009, 5, 12, 673

    CrossRef

  113. 113
    Robert J. Feeley, Farid Saad, Andre Guay, Abdulmaged M. Traish, Testosterone in men's health: a new role for an old hormone, Journal of Men's Health, 2009, 6, 3, 169

    CrossRef

  114. 114
    Farid Saad, Louis Gooren, The role of testosterone in the metabolic syndrome: A review, The Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 1-2, 40

    CrossRef

  115. 115
    W.J. Fávaro, C.R. Padovani, V.H.A. Cagnon, Ultrastructural and proliferative features of the ventral lobe of the prostate in non-obese diabetic mice (NOD) following androgen and estrogen replacement associated to insulin therapy, Tissue and Cell, 2009, 41, 2, 119

    CrossRef

  116. 116
    M Maggio, S Basaria, Welcoming low testosterone as a cardiovascular risk factor, International Journal of Impotence Research, 2009, 21, 4, 261

    CrossRef

  117. 117
    Dheeraj Kapoor, T Hugh Jones, Androgen Deficiency as a Predictor of Metabolic Syndrome in Aging Men, Drugs & Aging, 2008, 25, 5, 357

    CrossRef

  118. 118
    Louis Gooren, Can the administration of testosterone to men with late-onset hypogonadism be discontinued?, Journal of Men's Health, 2008, 5, 4, 366

    CrossRef

  119. 119
    Michael Zitzmann, Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism, Asian Journal of Andrology, 2008, 10, 3
  120. 120
    Polly E. Kintzel, Sandra L. Chase, Lisa M. Schultz, Timothy J. O'Rourke, Increased Risk of Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease in Men Receiving Androgen Deprivation Therapy for Prostate Cancer, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008, 28, 12
  121. 121
    Angela D. Mazza, Insulin Resistance Syndrome and Glucose Dysregulation in the Elderly, Clinics in Geriatric Medicine, 2008, 24, 3, 437

    CrossRef

  122. 122
    Payam Hakimian, Michael Blute, James Kashanian, Sherman Chan, David Silver, Ridwan Shabsigh, Metabolic and cardiovascular effects of androgen deprivation therapy, BJU International, 2008, 102, 11
  123. 123
    Louis Gooren, Obesity: new aspects, Journal of Men's Health, 2008, 5, 3, 249

    CrossRef

  124. 124
    Jing Ma, Haojie Li, Ed Giovannucci, Lorelei Mucci, Weiliang Qiu, Paul L Nguyen, J Michael Gaziano, Michael Pollak, Meir J Stampfer, Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis, The Lancet Oncology, 2008, 9, 11, 1039

    CrossRef

  125. 125
    Louis Gooren, Recent perspectives on the age-related decline of testosterone, Journal of Men's Health, 2008, 5, 1, 86

    CrossRef

  126. 126
    Paul D. Maroni, E. David Crawford, The benefits of early androgen blockade, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 2, 317

    CrossRef

  127. 127
    Peter Iversen, Martin Andreas Roder, The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer, Expert Review of Anticancer Therapy, 2008, 8, 3, 361

    CrossRef

  128. 128
    Louis Gooren, Siegfried Meryn, Ridwan Shabsigh, The metabolic syndrome: when is testosterone treatment warranted, Journal of Men's Health, 2008, 5, S, S40

    CrossRef

  129. 129
    R. Shabsigh, S. Arver, K. S. Channer, I. Eardley, A. Fabbri, L. Gooren, A. Heufelder, H. Jones, S. Meryn, M. Zitzmann, The triad of erectile dysfunction, hypogonadism and the metabolic syndrome, International Journal of Clinical Practice, 2008, 62, 5
  130. 130
    Rita R Kalyani, Adrian S Dobs, Androgen deficiency, diabetes, and the metabolic syndrome in men, Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 3, 226

    CrossRef

  131. 131
    Matthew R Smith, Androgen deprivation therapy for prostate cancer: new concepts and concerns, Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 3, 247

    CrossRef

  132. 132
    Louis Gooren, Androgens, visceral obesity and the risks for cardiovascular disease and diabetes mellitus, The Journal of Men's Health & Gender, 2007, 4, 1, 94

    CrossRef

  133. 133
    V. Venkateswaran, A. Q. Haddad, N. E. Fleshner, R. Fan, L. M. Sugar, R. Nam, L. H. Klotz, M. Pollak, Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts, JNCI Journal of the National Cancer Institute, 2007, 99, 23, 1793

    CrossRef

  134. 134
    Wendy Demark-Wahnefried, Mark M Moyad, Dietary intervention in the management of prostate cancer, Current Opinion in Urology, 2007, 17, 3, 168

    CrossRef

  135. 135
    D A Galvão, D R Taaffe, N Spry, R U Newton, Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer, Prostate Cancer and Prostatic Diseases, 2007, 10, 4, 340

    CrossRef

  136. 136
    K Suzuki, A Nukui, Y Hara, T Morita, Glucose intolerance during hormonal therapy for prostate cancer, Prostate Cancer and Prostatic Diseases, 2007, 10, 4, 384

    CrossRef

  137. 137
    TH Jones, Hypogonadism in men with type 2 diabetes, Practical Diabetes International, 2007, 24, 5
  138. 138
    Angela D. Mazza, John E. Morley, Metabolic syndrome and the older male population, The Aging Male, 2007, 10, 1, 3

    CrossRef

  139. 139
    Janet R. Walczak, Michael A. Carducci, Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease, Mayo Clinic Proceedings, 2007, 82, 2, 243

    CrossRef

  140. 140
    Janet R. Walczak, Michael A. Carducci, Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease, Mayo Clinic Proceedings, 2007, 82, 2, 243

    CrossRef

  141. 141
    Ithaar H. Derweesh, Christopher J. DiBlasio, Matt C. Kincade, John B. Malcolm, Kimberly D. Lamar, Anthony L. Patterson, Abbas E. Kitabchi, Robert W. Wake, Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer, BJU International, 2007, 100, 5
  142. 142
    M. M. Miner, A. D. Seftel, Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?, International Journal of Clinical Practice, 2007, 61, 4
  143. 143
    T. Hugh Jones, Testosterone Associations with Erectile Dysfunction, Diabetes, and the Metabolic Syndrome, European Urology Supplements, 2007, 6, 16, 847

    CrossRef

  144. 144
    Brian G. Choi, Mary Ann McLaughlin, Why Men's Hearts Break: Cardiovascular Effects of Sex Steroids, Endocrinology and Metabolism Clinics of North America, 2007, 36, 2, 365

    CrossRef

  145. 145
    Marcello Maggio, Fulvio Lauretani, Gian Paolo Ceda, Stefania Bandinelli, Shehzad Basaria, Alessandro Ble, Josephine Egan, Giuseppe Paolisso, Samer Najjar, E. Jeffrey Metter, Giorgio Valenti, Jack M. Guralnik, Luigi Ferrucci, Association Between Hormones and Metabolic Syndrome in Older Italian Men, Journal of the American Geriatrics Society, 2006, 54, 12
  146. 146
    Chrissie Giles, Hypogonadism might cause insulin resistance in prostate cancer, Nature Clinical Practice Endocrinology & Metabolism, 2006, 2, 5, 249

    CrossRef

  147. 147
    DANIEL A. GALV??O, KAZUNORI NOSAKA, DENNIS R. TAAFFE, NIGEL SPRY, LINDA J. KRISTJANSON, MICHAEL R. MCGUIGAN, KATSUHIKO SUZUKI, KANEMITSU YAMAYA, ROBERT U. NEWTON, Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients, Medicine & Science in Sports & Exercise, 2006, 38, 12, 2045

    CrossRef

  148. 148
    Kathryn Parr, Nutritional Management In Prostate Cancer,